Is Krystal Biotech, Inc. (NASDAQ:KRYS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Krystal Biotech, Inc. at current levels.
VYJUVEK is the proof of concept that gene therapy works as a topical, repeatable product. The pipeline is the real prize.
Where KRYS is headed
By end of 2027, Krystal will have done something no gene therapy company has managed before: turned a one-time concept into a recurring revenue product line. VYJUVEK is already running at roughly $400M+ annual revenue out of the US DEB market, and the European launch through the UK and Germany is now layering on. But the destination view isn't about DEB. It's about KB407 in cystic fibrosis and KB408 in alpha-1 antitrypsin deficiency reading out Phase 1 data that validates the redosable HSV-1 vector platform across inhaled and systemic delivery. If either works, the addressable market goes from a few thousand DEB patients to hundreds of thousands of CF and AAT patients, and the conversation shifts from 'rare disease biotech' to 'gene therapy platform company with a $30B+ TAM'.
Read the full Compass Direction on KRYS
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $309.75).
See the full KRYS analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Krystal Biotech, Inc. (NASDAQ:KRYS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Krystal Biotech, Inc. at current levels. VYJUVEK is the proof of concept that gene therapy works as a topical, repeatable product. The pipeline is the real prize.
What is KRYS's Compass Score?
Krystal Biotech, Inc. scores 89/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for KRYS?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the KRYS page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.